What the trial was testing
The ACeD enrolled 41 patients with celiac disease. The study was sponsored by Kanyos Bio and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was an early-stage trial — researchers are still confirming safety and getting an early look at how well the treatment works. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
No dose-limiting safety issues across all five dose levels tested.
The Lancet Gastroenterology & Hepatology · 2023 · NCT04248855
These findings — that safety issues at any dose of KAN-101 in this first-in-human celiac trial — were published in the The Lancet Gastroenterology & Hepatology and represent the headline result of the study.
Researchers tracked outcomes across 41 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with celiac disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
KAN-101 is still in development and not yet FDA-approved. The only proven treatment for celiac disease today is a strict, lifelong gluten-free diet. Several drugs aimed at celiac disease are in clinical trials. Ask a gastroenterologist about open trials if a strict gluten-free diet is not enough.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open celiac disease trials
Immune Responses to Gluten
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)
The investigators propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. The investigators hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits